Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thymalfasin - SciClone Pharmaceuticals

Drug Profile

Thymalfasin - SciClone Pharmaceuticals

Alternative Names: Thymosin-α-1; Tα 1; Zadaxin

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas at Austin
  • Developer SciClone Pharmaceuticals; sigma-tau SpA
  • Class Adjuvants; Antineoplastics; Antivirals; Oligopeptides; Thymus hormones
  • Mechanism of Action Th1 cell stimulants; Th2 cell inhibitors; Th2 cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Hepatitis B; Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Marketed Cancer; Hepatitis B; Hepatitis C
  • Phase III Sepsis
  • No development reported Liver cancer; Malignant melanoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 23 Jan 2019 SciClone Pharmaceuticals prematurely terminates a phase II trial in Non small cell lung cancer in Italy (NCT02906150)
  • 24 Jun 2018 Biomarkers information updated
  • 16 Sep 2016 SciClone Pharmaceuticals plans a phase I/II trial for Non-small cell lung cancer (Metastatic disease) in Italy (NCT02906163)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top